BioCentury
ARTICLE | Clinical News

Sapacitabine: Updated Phase II data

October 22, 2012 7:00 AM UTC

Cyclacel presented updated OS data from 3 arms in an open-label, U.S. Phase II trial in 63 elderly patients with MDS evaluating sapacitabine. Specifically, updated median OS was 291 days, up from 240 ...